Cullinan Oncology/CGEM

$22.69

0.04%
-
1D1W1MYTD1YMAX

About Cullinan Oncology

Cullinan Therapeutics, Inc., formerly Cullinan Oncology, Inc., is a biopharmaceutical company focused on developing modality-agnostic targeted therapies. It has a portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its pipeline includes CLN-619, CLN-978, Zipalertinib (CLN-081/TAS6417), CLN-049, CLN-418, and CLN-617. Its lead unpartnered program, CLN-619, is a humanized lgG1 monoclonal antibody (mAb) that binds to the stress induced ligands MICA and MICB (MICA/B), which are expressed on a variety of solid tumors and hematologic malignancies. CLN-978 is a novel, highly potent, half-life extended CD19xCD3 bispecific T cell engager construct. CLN-081/TAS6417 is a novel, orally available, covalent inhibitor of mutant epidermal growth factor receptor (EGFR). CLN-049 is a FLT3xCD3 T cell engaging bispecific antibody. CLN-418 is a B7H4 x 4-1BB bispecific immune activator.

Ticker

CGEM

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Nadim Ahmed

Employees

85

Headquarters

Cambridge, United States

CGEM Metrics

BasicAdvanced
$1.3B
Market cap
-
P/E ratio
-$3.14
EPS
-0.07
Beta
-
Dividend rate
$1.3B
-0.07259
$30.19
$7.64
772K
20.329
-27.85%
-29.05%
-29.31%
2.33
3.118
-358.25%

What the Analysts think about CGEM

Analyst Ratings

Majority rating from 9 analysts.
Buy

Price Targets

Average projection from 7 analysts.
45.44% upside
High $40.00
Low $28.00
$22.69
Current price
$33.00
Average price target

CGEM Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$37M
55.88%
Profit margin
0%
NaN%

CGEM Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 13.1%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.82
-$0.91
-$0.54
-$0.86
-
Expected
-$0.97
-$0.92
-$0.96
-$0.99
-$0.73
Surprise
-15.46%
-1.27%
-43.83%
-13.1%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Cullinan Oncology stock?

Cullinan Oncology (CGEM) has a market cap of $1.3B as of May 30, 2024.

What is the P/E ratio for Cullinan Oncology stock?

The price to earnings (P/E) ratio for Cullinan Oncology (CGEM) stock is 0 as of May 30, 2024.

Does Cullinan Oncology stock pay dividends?

No, Cullinan Oncology (CGEM) stock does not pay dividends to its shareholders as of May 30, 2024.

When is the next Cullinan Oncology dividend payment date?

Cullinan Oncology (CGEM) stock does not pay dividends to its shareholders.

What is the beta indicator for Cullinan Oncology?

Cullinan Oncology (CGEM) has a beta rating of -0.07. This means that it has an inverse relation to market volatility.

What is the Cullinan Oncology stock price target?

The target price for Cullinan Oncology (CGEM) stock is $33, which is 45.44% above the current price of $22.69. This is an average based on projections from 7 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Cullinan Oncology stock

Buy or sell Cullinan Oncology stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing